Implementing the New EU Legislation on Advanced Therapy Medicinal Products
This article was originally published in RAJ Devices
Executive Summary
The large number of people who attended the European Medicines Agency’s first workshop on advanced therapy medicinal products reflects the interest of stakeholders for this rapidly evolving field. Around 160 individuals from regulatory authorities, industry and academia attended the much anticipated meeting, which took place in London on 3 April, a month after having been postponed due to severe weather conditions. Delegates from the EMEA and representatives from the EMEA’s new Committee for Advanced Therapies presented the key implementation aspects surrounding the relevant legislation, Regulation (EC) No 1394/2007 on Advanced Therapy Medicinal Products, which has been in force since 30 December 2008.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.